What is the recommended workup for a patient with new onset angina?

Workup of New Onset Angina

All patients with new onset angina should undergo immediate 12-lead ECG (within 10 minutes), cardiac biomarkers (troponin preferred), and risk stratification, followed by coronary computed tomographic angiography (CCTA) as the first-line anatomical test for most patients, while simultaneously initiating aspirin 75-325 mg daily and sublingual nitroglycerin. 1

Immediate Assessment (Emergency Department or Outpatient Setting)

Clinical Evaluation and ECG

• Obtain 12-lead ECG within 10 minutes of presentation for all patients with chest discomfort or anginal equivalent symptoms 1
• If initial ECG is non-diagnostic but symptoms persist with high clinical suspicion, perform serial ECGs at 15-30 minute intervals to detect evolving ST-segment changes 1
• Document specific characteristics: duration, quality, radiation, precipitating factors, and response to rest or nitroglycerin

Cardiac Biomarkers

• Measure cardiac-specific troponin (preferred marker) in all patients presenting with chest discomfort consistent with acute coronary syndrome 1
• If initial troponin is negative within 6 hours of symptom onset, repeat measurement at 8-12 hours after symptom onset 1
• This distinguishes unstable angina/NSTEMI from stable angina and guides urgency of management

Risk Stratification

Use the ACC/AHA risk stratification criteria to categorize patients 1:

High Risk Features:

• Prolonged rest angina (>20 minutes)
• Pulmonary edema likely due to ischemia
• Transient ST-segment changes >0.5 mm with rest angina
• Elevated troponin (>0.1 ng/mL)
• Hemodynamic instability
• Recent syncope or presyncope

Intermediate Risk Features:

• Rest angina >20 minutes, now resolved
• Nocturnal angina
• Age >70 years
• T-wave changes on ECG
• Slightly elevated troponin (0.01-0.1 ng/mL)

Low Risk Features:

• New onset angina (within 2 weeks to 2 months)
• Increased angina frequency/severity/duration
• Normal or unchanged ECG
• Normal cardiac biomarkers

Diagnostic Testing Strategy

First-Line Anatomical Testing

Coronary CT angiography (CCTA) is the preferred first-line diagnostic test for patients with new onset stable angina 2, 3. This represents a shift from older guidelines that emphasized functional testing:

• Higher sensitivity compared to stress testing
• Detects nonobstructive atherosclerosis that would be missed by functional tests, improving risk assessment
• Cost-effective based on PROMISE trial analysis
• Better diagnostic yield in patients with angina and nonobstructive CAD

When to Use Stress Testing Instead

Reserve stress imaging (not exercise ECG alone) as initial test for patients with:

• Rest ST-segment depression >1 mm
• Complete left bundle-branch block
• Ventricular paced rhythm
• Pre-excitation syndrome (WPW)
• Previous revascularization (PCI or CABG) 4
• Inability to exercise (use pharmacologic stress imaging)

Common Pitfall: Exercise ECG alone has limited diagnostic utility in many patients and should not be first-line unless CCTA is unavailable 5, 4

Essential Laboratory Testing

Measure the following in all patients 5:

• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Fasting glucose or HbA1c (diabetes screening)
• Blood pressure measurement
• Complete blood count (rule out anemia)
• Thyroid function if clinically indicated

Immediate Medical Therapy Initiation

Start Immediately (Class I Recommendations)

Antiplatelet Therapy:

• Aspirin 75-325 mg daily (start immediately unless contraindicated) 6, 5, 7
• If aspirin contraindicated: Clopidogrel 75 mg daily 6

Sublingual Nitroglycerin:

• Provide sublingual or spray nitroglycerin with written and verbal instructions 6, 7
• Instruct: Take 1 dose if angina lasts >2-3 minutes after stopping activity
• If no relief in 5 minutes, take second dose
• Call 9-1-1 if pain persists >15-20 minutes or after 3 doses 6, 8

Beta-Blockers:

• Initiate beta-blocker therapy unless contraindicated 6, 9
• Particularly important if concurrent hypertension, prior MI, or LV dysfunction
• Critical warning: Patients must not stop beta-blockers abruptly; taper over 4 weeks if discontinuation needed 5

Additional Therapies Based on Risk Factors

Lipid Management:

• High-intensity statin for LDL >100 mg/dL (target <70 mg/dL in high-risk patients) 6
• Consider PCSK9 inhibitors, ezetimibe, or icosapent ethyl if LDL remains elevated 10

ACE Inhibitors:

• Start ACEI if patient has heart failure, LV dysfunction (EF <40%), hypertension, or diabetes 6

Additional Antianginal Therapy:

• If symptoms persist on beta-blocker alone, add dihydropyridine calcium channel blocker 9
• Second-line options: long-acting nitrates, ranolazine, nicorandil, or trimetazidine 9

Referral Criteria

Immediate cardiology referral (same day) for 5:

• High-risk features on risk stratification
• Symptoms uncontrolled on maximal doses of 2 antianginal drugs
• Uncertain diagnosis requiring clarification
• Hemodynamic instability or concerning ECG changes

Urgent referral (within days) for:

• Intermediate-risk features
• Need for prognostic investigation
• Consideration for revascularization

Refer directly for angiography (not stress testing) if symptoms remain uncontrolled despite optimal medical therapy 5

Patient Education Requirements

Before discharge or at initial visit, provide written and verbal instructions on 6, 7:

• Medication types, doses, purposes, and side effects
• Nitroglycerin use protocol (detailed above)
• Warning signs requiring immediate 9-1-1 call: chest pain >15-20 minutes, pain unrelieved by 3 nitroglycerin doses, or worsening pattern of angina
• Smoking cessation (mandatory counseling) 5
• Weight reduction if BMI elevated 5
• Exercise recommendations (moderate exercise improves outcomes) 5
• Enrollment in cardiac rehabilitation program 6

Key Differences from Older Guidelines

The 2024 ESC guidelines 9 and recent evidence 10, 2 emphasize:

1. CCTA as first-line test rather than functional testing
2. Individualized antianginal selection based on hemodynamics and comorbidities, not rigid beta-blocker preference
3. Revascularization reserved for quality of life improvement, not mortality reduction (based on ISCHEMIA trial)
4. Novel preventive therapies (SGLT2 inhibitors, GLP-1 agonists in diabetics) improve cardiovascular outcomes

Critical Caveat: While older guidelines 6, 5 from 1996-2000 are included in the evidence, prioritize the 2024 ESC 9, 2014 AHA/ACC 7, and 2013 ACCF/AHA 1 recommendations for contemporary practice, supplemented by recent research 10, 2 supporting CCTA-first strategies.